Form 4: Fennec Pharmaceuticals Director Exercises Options and Sells Shares for Tax Obligations

Fennec Pharmaceuticals Director Chris A. Rallis reported the exercise of 2,127 options at $2.35 per share and the subsequent sale of 1,119 shares at $8.71 to cover tax liabilities, as part of a pre-arranged 10b5-1 plan.

Summary

• Chris A. Rallis, a Director of Fennec Pharmaceuticals Inc. (FENC), reported transactions on July 7, 2025.
• Rallis acquired 2,127 common shares by exercising options at a price of $2.35 per share.
• This option exercise was conducted under a Rule 10b5-1 plan adopted on August 17, 2023.
• Concurrently, Rallis disposed of 1,119 common shares at $8.71 per share.
• The sale of shares was specifically to satisfy tax obligations arising from the option exercise.
• Following these transactions, Rallis directly beneficially owns 54,792 common shares and 178,406 options.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a director exercised options, realizing value, and the subsequent sale was specifically to cover tax obligations, not a discretionary divestment of shares. The transactions were also conducted under a pre-arranged 10b5-1 plan.

Positives

• Director Chris A. Rallis exercised options, indicating a realization of value from previously granted equity.
• The transactions were conducted under a pre-arranged Rule 10b5-1 plan, adopted on August 17, 2023, which suggests planned and not opportunistic trading.
• The exercise price of $2.35 is significantly lower than the sale price of $8.71, indicating a substantial gain on the exercised options.

Negatives

• A portion of the exercised shares (1,119 shares) was sold, which reduces the director's direct equity holding in the company, although this was for tax purposes.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency on insider trading activity, specifically a director's exercise of options and subsequent sale for tax purposes.

Key Dates

Keywords

Fennec Pharmaceuticals, FENC, Form 4, Insider Trading, Option Exercise, Share Sale, 10b5-1 Plan, Director Transactions, Equity Compensation, Chris Rallis